PCV53 Goal Directed Perfusion (Gdp): A Differential Cost Analysis In Uk And Us  by Povero, M. & Pradelli, L.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A481
and after excluding the outliers and longer than 90 days LOS, the data included 
3,428 patients. The estimated mean difference using the average CMG+ estimate 
for the whole hospital episode costs were about $500 higher than actual costs. The 
median CMG+ cost were most accurate estimates for per diem costs, which was 
about $20 higher than actual cost. 2 comorbidities were dropped from the regression 
due to multicollinearity. Using average CMG+ estimate for whole hospital episode 
costs, 10/13 comorbidity coefficients were found to be statistically equivalent to the 
coefficients in a separate regression using actual cost. ConClusions: This study 
shows that various derivations of costing proxies using the CMG+ methodology 
produce relatively accurate cost estimates for AMI patients when actual cost are 
not available. Based on the available patient data and the context of use of the cost 
estimates, different methods will be optimal.
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objeCtives: Hypertension is a chronic condition, directly linked to cardiovascular 
diseases. Therefore, the monitoring of blood pressure (BP) is of utmost importance in 
order to avoid BP-related adverse clinical outcomes. This study aimed at comparing 
the health resources consumed and the subsequent costs for hypertension man-
agement using home blood pressure monitoring alone (HBPM) vs combined office 
measurements and ambulatory blood pressure monitoring (C/ABPM). Methods: 
A total of 116 previously untreated, hypertensive subjects were randomized to use 
either HBPM or C/ABPM for antihypertensive treatment initiation and titration. The 
analysis involved all health resources (BP measurements/outpatient visits, labora-
tory and other tests, pharmaceutical therapy) utilized within 12-months follow up, 
their respective costs, and efficacy (hypertension control). A 5-year projection was 
applied assuming (a) continuation of stable treatment as in the end of first year (for 
both arms), (b) single ABPM/year in C/ABPM group, (c) 2 visits/year in HBPM group 
and 3 in ABPM. Results: The total cost of hypertension management regardless 
of BP measurement method was calculated at 1,404.8€ /patient (laboratory tests: 
50.4%, BP measurements+outpatient visits: 32.4%, pharmaceuticals: 17.1%). In HBPM 
group, total cost was 1,336.0€ /patient vs 1,473.5€ /patient in C/ABPM group (p< 0.001). 
Findings suggested that the cost of treatment did not differ between the two groups 
(233.1 vs 247.6€ /patient respectively, p= NS), while BP measurements+outpatient vis-
its were estimated at 393.9€ /patient in HBPM arm and 516.9€ /patient in C/ABPM arm 
(p< 0.001). For subsequent years (> 1), expenditures were estimated at 348.9€ /patient 
for HBPM vs 440.2€ /patient for C/ABPM group (p< 0.001), whereas for a 5-year projec-
tion, 2,731.4€ /patient and 3,234.3€ /patient respectively (p< 0.001). ConClusions: 
C/ABPM strategy presented a higher first year cost compared to HBPM, while the 
same trend was unveiled in 5-year projection. Effective hypertension management 
through the appropriate strategies is of paramount importance considering its high 
prevalence; ergo, even small differences in the cost of applying them could have 
substantial impact on health expenditures.
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objeCtives: Literature has failed to demonstrate the clear superiority of Drug-Eluting 
Stenting (DES) for stable coronary artery diseases on survival as compared to the bare-
metal stenting (BMS). This study aimed to compare the health care utilization and 
the costs between drug-eluting stenting (DES) and bare-metal stenting (BMS). We also 
examined factors that influenced cumulative costs of these two groups. Methods: 
We conducted a retrospective cohort study based on the NHI program. Patients who 
had coronary stenting between Jan. 2007 and Dec. 2008 were recruited and followed 
through the end of 2010. Both groups were matched on 2: 1 by propensity score which 
adjusted sex, age, stent number and Charlson comorbidity index (CCI). We estimated 
cumulative medical cost for these two matched group by conducting the Kaplan-
Meier Sample Average (KMSA) estimates. Regression analysis was used to explore the 
predictors of cost. Results: The mean age in both groups was around 66 years. After 
propensity score matching, we had a total of 966 patients; 644 in BMS group and 322 
in DES group. KMSA estimates (discounted 3.5%) showed that DES group had a higher 
3-year cumulative total outpatient cost at US$ 6,867 and heart related outpatient 
cost at US$ 2,548 as compared to BMS group, which were US$7,668 and US$ 3,302 
respectively (1US$= 30 NTD). The heart related inpatient cost was similar between two 
groups. The significant predictors of heart-related outpatient costs were stent type, 
premium and CCI. The predictors of heart-related inpatient costs were stent type, 
stent number, CCI and procedure for acute coronary syndrome (ACS). ConClusions: 
In Taiwan, NHI reimburses DES and BMS at the same price, and hospitals can balance 
billing for the DES. We found that even after adding the extra national average out-
of-pocket payment to DES, DES still was a cost-effective procedure.
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objeCtives: High oxygen delivery (DO2) during cardiopulmonary bypass (CPB) 
is associated with better renal outcome in cardiac surgery. Traditional perfusion 
(TP) techniques, targeted on body surface area and CPB temperature, achieves high 
DO2 in about 50% of the cases while a goal directed perfusion (GDP) approach can 
lead to more than 90% of cases achieving high DO2 with a consequent reduction 
priate anticoagulation are recognised, but full implementation can be difficult and 
costly. Therefore the development of models such as this can support the planning 
process allowing stakeholders to discuss how best they can reach the target of full 
implementation. The model is flexible and can be adapted to suit different payers.
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objeCtives: Mitral Regurgitation (MR) is a cardiac disease resulting in backflow 
of blood from the left ventricle to the left atrium which could increase the risk of 
heart failure and mortality. Half of severe MR patients are not considered eligi-
ble to surgery (valve repair or replacement) and receive a medical treatment. MR 
patient management could benefit from usage of Mitraclip, a transcatheter device, 
which enables percutaneous edge-to-edge repair to treat MR. The cost-effectiveness 
model presented here compares Mitraclip therapy versus medical standard care 
treatment. Methods: A four-state Markov model (Death, MR grade 0, MR grade I 
/II, MR grade III/ IV) has been developed. In each state patients could be hospital-
ized or not. A national payer’s perspective was chosen with a 5 year time horizon. 
Primary and secondary endpoints were respectively the number of deaths and of 
hospitalizations avoided. Data were obtained from the EVEREST II high-risk study 
and from french cost analysis. Results: Within the time horizon analyzed, 276 
further deaths could be avoided by using Mitraclip strategy out of 1000 patients 
with MR, compared to medical treatment. The Incremental Cost Effectiveness Ratio 
(ICER) is estimated at € 93,000 per death averted with cumulative cost on five years. 
Sensitivity analysis shows that the cost of the initial surgery and the cost of the 
device where the two most sensitive variables. Costs of managing MR are higher for 
the Mitraclip option during the first year (€ 29,894 for Mitraclip compared to € 8,557 
for medical treatment) option due to the cost of the device and surgery, whereas 
this is inversed from the second year onwards (€ 8,557 for the medical option vs. 
€ 3,122 for Mitraclip). Therefore, an average ICER (20 720€ per death averted) has also 
been calculated. ConClusions: Mitraclip might represent a new economically 
attractive treatment option for MR patients at high-risk which increases survival.
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objeCtives: 1) Analyze whether a testing strategy using the biomarker 
Lp-PLA2would improve clinical and economic outcomes vs. ESC-SCORE alone in 
Germany for 50-70 year-olds. 2) Evaluate the potential budget impact for payers.  
Methods: To decide the treatment strategy for patients with moderate risk for 
cardiovascular events is a challenge. They would usually not receive statin treat-
ment in Germany. For further risk stratification there is a need to identify patients 
with vulnerable plaques. When an arterial plaque becomes unstable Lp-PLA2is 
released, which indicate that these patients could benefit from treatment to pre-
vent future cardiovascular events. An integrated cost-effectiveness and budget 
impact model was constructed. Lp-PLA2increased the adjusted risk for CVD events 
in the moderate ESC-SCORE population by > 2 fold in the German LURIC Study 
Cohort (HR 2.23,95% CI 1.15-4.32; P= 0.018). Efficacy of statin treatment relevant 
costs were obtained from literature. A range of sensitivity analyses were per-
formed. Results: The cost-effectiveness and the budget impact analyses used a 
theoretical population of 1 million, of which 14% were 50-70 year olds with mod-
erate cardiovascular risk. The total 10-year discounted and adherence adjusted 
net cost savings from implementing the Lp-PLA2 testing strategy was € 19 million, 
or € 156 per Lp-PLA2tested patient. The 10-year accumulated number of deaths 
averted by the Lp-PLA2 testing strategy was 611, or 17 incremental discounted 
life-days and 2.2 incremental discounted event-free life-months per Lp-PLA2tested 
patient. Projected to whole of Germany’s population aged 50-70 the potential 
annual discounted savings from the Lp-PLA2testing strategy would be € 180 million. 
The potential number of deaths averted per year would be 5,030. ConClusions: 
Our results indicate that the Lp-LPA2 testing strategy is both cost saving and pro-
vide reduction in mortality and morbidity. The implementation of Lp-LPA2 testing 
strategy should be considered in Germany.
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objeCtives: This study compares differences in actual hospital costs and Case 
Mixed Group (CMG+) costs (Canadian version of the Diagnosis Related Group), for 
patients with acute myocardial infarction (AMI) in Edmonton, Alberta. Methods: 
New AMI (ICD-10 code I21) patients (no AMI hospitalization within one year) hos-
pitalized in Edmonton area hospitals between April 1,2006 and March 30,2009 were 
segmented into CMG+ categories by the Canadian Institute for Health Information. 
The differences between actual hospital cost and CMG+ cost were analyzed by com-
paring the mean and median differences between costs for each patient and trim-
ming out 5% of high and low cost patients and excluding patients with longer than 
90 days of hospitalization. 15 comorbidities were derived from secondary diagnostic 
codes and regressed against CMG+ costs and actual costs independently. The coef-
ficients between the two separate regressions are then tested for statistical equiva-
lence using the Wald test. Results: The data included 4,734 new AMI patients, 
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model was a hospital in the United States (US). Clinical data was obtained from US 
pivotal studies for the Medtronic stent system and the competing stent systems. The 
competition arm (Competition) was created by pooling the pivotal study data for the 
current stent systems manufactured by Gore, Endologix, and Cook. Cost data was 
obtained from the Premier database (2011-2012) and augmented with the published 
literature. All costs were adjusted to 2013 dollars. The model estimated the costs 
associated with the following utilization outcomes: procedure time, transfusion rate, 
intensive care unit (ICU) length of stay (LOS), and general ward LOS. The following 
adverse events were considered: myocardial infarction, respiratory failure, acute 
renal failure, stroke/TIA, and second endovascular procedure within 12 months of 
the initial procedure. Sensitivity analysis was performed to assess the impact of 
imputed data, and one-way sensitivity analysis was performed for each parameter.  
Results: The expected costs for a hospital related to the above utilization and 
adverse event were $8,463 for Medtronic’s stent graft system and $11,380 for the 
Competition. Fifty-six percent of the $2,917 difference was attributable to improved 
utilization associated with Medtronic’s stent graft compared to the Competition. 
Adverse events and secondary endovascular procedures accounted for 25% and 19% 
of the difference, respectively. These results were robust to alternative sensitivity 
analyses. ConClusions: This analysis suggested that Medtronic’s current stent 
graft is associated with cost savings compared to Competition for the above param-
eters. Future research is necessary to examine if these results are maintained based 
upon a head-to-head clinical study of EVAR stent systems.
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objeCtives: ADVANCEIII trial showed that a long detection programming reduces 
all delivered therapies as well as inappropriate shocks in patients implanted with 
implantable cardioverter defibrillator (ICD). The purpose of this Advance III sec-
ondary analysis was to assess the impact of long detection on hospitalizations (H), 
length of stay (LOS) and associated costs for the health care system. Methods: 
1902 patients enrolled in the ADVANCEIII Trial: 948 patients randomized to long 
detection (NID 30/40) and 954 to short setting (NID 18/24). All hospitalizations 
were reviewed and classified according to ICD9CM codes and, consequently, to the 
corresponding Diagnosis-Related Groups (DRGs). Costs correspond to the specific 
public tariffs for the DRGs applied. The prospective was of a single-payer agent 
(Italian Ministry of Health). Results: Over a median period of 12 months, rates 
of overall and cardiovascular hospitalizations (CV) were lower in the long detec-
tion group (43.8*100 pts/years (39.6-48.4) vs 52.3*100 pts/years (47.7-57.3), IRR: 0.84 
(0.73-0.96) p= 0.005,32.7*100 pts/years (29.1-36.7) vs 40.3*100 pts/years (36.2-44.6), 
IRR (95% CI): 0.81 (0.69-0.95) p= 0.004 respectively). Patients programmed with a 
long detection had shorter LOS (overall H: 407days (394-421) vs 470 days (456-484), 
IRR: 0.87 (0.83-0.91) p< 0.001; CV: 298 days (287-309) vs 368 days (356-381), IRR: 0.81 
(0.77-0.85) p< 0.001) and lower mean hospital cost per patient-year compared with 
patients with nominal programming (overall H: 1.311 € (1.309 € - 1.314 € ) versus 
1.528€ (1.525€ - 1.530€ ) IRR: 0.86 (0.86-0.86) p< 0.001; CV: 1.100 € (1.098 € - 1.103 € ) 
versus 1.339 € (1.337 € - 1.342 € ) IRR: 0.86 (0.86-0.86) p< 0.001). ConClusions: 
A long detection window was associated with a reduction in hospitalization rates, 
total length of stay and cost per patients both for all-causes and cardiovascular 
related events.
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objeCtives: The rising cost of treatment of peripheral arterial disease and the 
growing incidence of this disease led to economic analysis of arterial disease. With 
the increasing price of modern instrumentation, it is appropriate to evaluate not 
only clinical efficiency, but also intervention economics. This study aims to create a 
recommendation for choosing the most effective treatment based on both economic 
data and clinical outputs of the disabled superficial femoral artery. Methods: The 
methods chosen were reviewed from clinical outputs for treatment effectiveness, 
multiple-criteria decision-making for the synthesis of treatment effects, analysis of 
costs at the selected interventions and cost-effectiveness analysis. Results: The 
four clinical outputs used in the study as a criterion by the research of the clinical 
studies were primary patency, technical success, patient survival and limb salvage at 
the year of operation. The weights of each criterion, and the preferences of the inter-
ventions were counted. The sequence of interventions was set by the AHP method: 
PTA (35.6%), PTA/S (33.9%) and bypass (30.6%) and method of weighted sum: PTA/S 
(56%), bypass (55%) and PTA (42%). From the view of both health insurance payer and 
health care provider, where the direct medical expenditures were included, the order 
of intervention was the same: PTA, bypass and PTA/S. The cost-effectiveness was 
calculated for both, and the PTA intervention achieved the best results. Incremental 
expenditures by unit of effect was calculated for each effect: ICER or the domination 
of one intervention over another was set. Ratio of the ICER was generally higher for 
PTA/S compared to bypass. In the sensitive analysis was determined the influence of 
in Acute Kidney Injury (AKI) rate of about 40%. Aim of this study is to perform an 
economic evaluation of GDP strategy with respect to TP in UK and US. Methods: 
A Discrete Event Simulation model was developed to compare TP and GDP strategy 
in patients undergoing CPB. The patient’s pathways from operation to discharging 
from hospital was simulated: AKI incidence, in-hospital mortality, hospital length 
of stay, transfusions were correlated to probability to achieve high DO2 target using 
published correlations. National perspective was adopted to calculate costs asso-
ciated to each event while GDP strategy was exploited considering card and data 
management system (DMS) cost per patient. Results: GDP strategy saved more 
than 3 days in hospital and 11% of AKI episodes. The cost-saving is 2,821 £ in UK 
and 3,206 $ in US; the cost of card and DMS (79 £ in UK, 110 $ in US) is completely 
offset by savings in hospital stay that result the main driver in cost (2,886 £ in UK, 
3,222 $ in US). Deterministic sensitivity analysis shows that the total savings are 
mainly influenced by hospital LOS, cost per day both in ICU and in ward, and nadir 
haematocrit during CPB. ConClusions: GDP seems to improve significantly the 
main outcomes related to CPB surgery, when compared to TP techniques. Additional 
costs due to perform GDP strategy have no impact on the total cost since completely 
offset by the savings in hospital cost.
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objeCtives: The use of polypills in the prevention of cardiovascular disease is 
mooted to reduce costs compared with current practice, yet there is very little 
prospectively-collected data to support this claim. The present study compares 
the ‘real-world’ costs of a polypill strategy against usual care among Australians 
with established cardiovascular disease or at high estimated cardiovascular 
risk. Methods: A ‘within trial’ cost analysis from the Australian health system 
perspective of polypill-based care versus usual care with separate medications 
was conducted using data from the pragmatic randomised controlled trial Kanyini 
Guidelines Adherence to Polypill (Kanyini GAP) and linked health service and medi-
cation claims data. The primary outcome, estimated with generalised linear models, 
was mean health service and pharmaceutical expenditure, per patient per year. 
All costs during the trial, conducted from 2008-2012, were inflated to $AUD 2012 
prices. Results: A statistically significantly lower mean pharmaceutical expendi-
ture of $989 (95%CI 648 to 1331) per patient per year in the polypill arm compared 
to usual care (P< 0.001, adjusted, excluding polypill cost). No significant differences 
were observed in annual non-hospital health service expenditure ($40, 95%CI -202 to 
281 per patient). ConClusions: This study provides evidence that a cardiovascular 
disease polypill strategy has the potential to produce significant cost-savings to 
health systems. At an estimated reimbursement cost of $1 per day for the polypill, 
these savings would have amounted to over $600 per patient per year. Cost-savings 
would accrue to patients also, given fewer prescription charges. Linking health 
service and medication claims data with data from a pragmatic randomised con-
trolled trial has provided an avenue to assess the real-world cost implications of 
introducing this new technology into clinical practice.
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objeCtives: There is a growing prevalence of diabetes mellitus (DM) among chronic 
diseases in the world. Currently there are over 135 million people with diabetes 
worldwide with estimates reaching 300 million in 2025. Developing countries con-
centrate two thirds of these patients and it is known that the economic burden of 
chronic diseases generate high costs for the health system and social welfare as 
a function of mortality and premature disability. The objective of the study was to 
investigate the impact on hospital costs of treating a patient with ischemic heart 
disease and DM, compared with cardiac patients without DM, in a cardiology hospi-
tal of high complexity Ministry of Health in Brazil. Methods: observational study 
of historical cohort of 421 diabetic heart disease (CD) and non diabetic (CND), from 
January 2009 to March 2010 in cardiology hospital of high complexity of the Unified 
Health System (SUS) in Brazil. Were only covered the direct medical costs of hos-
pitalizations. The costs of the study population (CD and CND) were grouped into 
surgery, and clinical treatment obtained by two different approaches (top-down and 
bottom-up estimates), and subsequently analyzed and compared using R software 
version 3.0. Results: No differences between groups were observed. Cost of sur-
gery: CND = U. S. $ 2937.55 and U. S. $ 3024.51 = CD (p = 0.319). Medical Treatment: 
CND = U. S. $ 685.09 and U. S. $ 304.11 = CD (p = 0.218). Values are expressed as 
medians. ConClusions: studies analyzing these conditions separately describe 
high expenses resulting from the treatment of diabetes and cardiovascular disease. 
We can infer from the results of this study that the diabetic patient cardiac does not 
generate a significant financial impact for a cardiology hospital of high complexity.
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objeCtives: To perform a cost comparison analysis of Medtronic’s current stent 
graft system compared to currently competing stent graft systems for endovas-
cular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAA). Methods: 
A simulation model was constructed using Microsoft Excel. The perspective of the 
